Loading...
•
Mar 31, 2022
Esperion Q1 2022 Earnings Report
Esperion's Q1 2022 financial results were reported, featuring a 109% year-over-year increase in U.S. net product revenue and progress in the CLEAR Outcomes trial.
Key Takeaways
Esperion reported a strong first quarter with a 135% increase in total revenue compared to the previous year, driven by growth in U.S. product revenue and royalties. The company is advancing its CLEAR Outcomes trial and reaffirming its financial outlook for 2022.
U.S. net product revenue grew approximately 109% year-over-year to $13.4 million.
Retail prescription equivalents grew 56.7% year-over-year.
CLEAR Outcomes trial is approaching 95% MACE accumulation.
Partner Daiichi Sankyo continued European rollout of NILEMDO® and NUSTENDI®.
Esperion
Esperion
Esperion Revenue by Segment
Revenue by Segment
U.S. Net Product Revenue
CapyFin.comCollaboration Revenue
CapyFin.com Forward Guidance
Esperion is reaffirming its prior operational expense guidance.
Positive Outlook
- Research and Development expenses for the full year 2022 are expected to be $100 million to $110 million.
- Selling, General and Administrative expenses for the full year 2022 are expected to be $120 million to $130 million.
- Esperion expects full-year 2022 operating expenses to be approximately $220 million to $240 million.
- Operating expenses include $25 million of non-cash, stock-based compensation expense.
Revenue & Expenses
Visualization of income flow from segment revenue to net income